EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a virulent O’nyong’nyong challenge model to determine heterologous protection mediated by a hydrogen peroxide-inactivated chikungunya virus vaccine

Whitney C Weber, Zachary J Streblow, Takeshi F Andoh, Michael Denton, Hans-Peter Raué, Ian J Amanna, Dawn K Slifka, Craig N Kreklywich, Irene Arduino, Gauthami Sulgey, Magdalene M Streblow, Mark T Heise und 2 weitere

PLOS Neglected Tropical Diseases · 17.03.2025 · 19 (3) · e0012938

DOI: 10.1371/journal.pntd.0012938 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 17.03.2025. Verfasst von Whitney C Weber und 13 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America. Hauptthemen laut MEDLINE: Chikungunya Fever, Viral Vaccines, Chikungunya virus, O'nyong-nyong Virus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, Defense Threat Reduction Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

O’nyong-nyong virus (ONNV) is a mosquito-transmitted alphavirus identified in Uganda in 1959. The virus has potential for enzootic and urban transmission cycles, and in humans, ONNV infection manifests as fever, rash, and joint/muscle pain that can persist. There are currently no specific vaccines or antiviral treatments for ONNV. Since highly passaged alphaviruses often lose pathogenic features, we constructed an infectious clone for ONNV-UVRI0804 (ONNV 0804 ), a 2017 isolate from a febrile patient in Uganda. Viral replication for ONNV 0804 was compared to the highly passaged strain, ONNV UgMP30 , and ONNV UgMP30 replicated to higher levels in human dermal fibroblasts and Vero cells, but both viruses replicated similarly in C6/36 and mouse embryonic fibroblast cells. We performed a head-to-head comparison of in vivo virulence in both immunocompetent C57BL/6 mice and interferon deficient AG129 mice. In both mouse strains, ONNV 0804 was substantially more pathogenic than ONNV UgMP30 . Unlike ONNV UgMP30 , ONNV 0804 caused significant footpad swelling and broader tissue distribution with higher vRNA loads at both 5- and 43-days post-infection (dpi) relative to ONNV UgMP30 . This finding indicates that ONNV can persist in joint and muscle tissues for long periods of time, which has been associated with chronic arthritogenic human disease. In AG129 mice, ONNV 0804 caused a more rapid onset of disease, higher viremia, and a >800-fold increase in virulence. Previous studies have shown that CHIKV infection or vaccination can provide cross-reactive immunity to ONNV. To determine if a CHIKV vaccine can protect against the more virulent ONNV 0804 strain, we vaccinated mice with a hydrogen peroxide-inactivated CHIKV vaccine, HydroVax-CHIKV. Neutralizing antibody titers were determined against ONNV 0804 and CHIKV and animals were challenged with ONNV 0804 . An optimized two-dose vaccination regimen of HydroVax-CHIKV protected against lethal infection and reduced virus-associated arthritogenic disease. These data indicate that we have developed new and robust models for studying severe ONNV disease and that HydroVax-CHIKV vaccination can protect against infection with a highly pathogenic contemporary strain of ONNV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chikungunya FeverViral VaccinesChikungunya virusO'nyong-nyong VirusHydrogen PeroxideImmunity, HeterologousAnimalsMiceMice, Inbred C57BLVaccines, InactivatedHumansDisease Models, AnimalChlorocebus aethiopsFemaleVirus ReplicationVero CellsAntibodies, ViralAntibodies, NeutralizingVirulence

Substanzen

Viral VaccinesVaccines, InactivatedHydrogen PeroxideAntibodies, ViralAntibodies, Neutralizing

Autor:innen und Institutionen

  • Vaccine & Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.
  • Division of Pathobiology & Immunology, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
  • Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, United States of America.
  • Najít Technologies, Inc., Beaverton, Oregon, United States of America.
  • Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy.
  • Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

ORCID-Profile: Daniel N Streblow

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • Defense Threat Reduction Agency
  • Foundation for the National Institutes of Health

Zitieren

APA

Weber, W. C., Streblow, Z. J., Andoh, T. F., Denton, M., Raué, H. P., Amanna, I. J., Slifka, D. K., Kreklywich, C. N., Arduino, I., Sulgey, G., Streblow, M. M., Heise, M. T., Slifka, M. K., & Streblow, D. N. (2025). Development of a virulent O’nyong’nyong challenge model to determine heterologous protection mediated by a hydrogen peroxide-inactivated chikungunya virus vaccine. PLOS Neglected Tropical Diseases, 19(3), e0012938. https://doi.org/10.1371/journal.pntd.0012938

Vancouver

Weber WC, Streblow ZJ, Andoh TF, Denton M, Raué HP, Amanna IJ, et al. Development of a virulent O’nyong’nyong challenge model to determine heterologous protection mediated by a hydrogen peroxide-inactivated chikungunya virus vaccine. PLOS Neglected Tropical Diseases. 2025;19(3):e0012938. doi:10.1371/journal.pntd.0012938

BibTeX
@article{Weber2025,
  author = {Weber, Whitney C and Streblow, Zachary J and Andoh, Takeshi F and Denton, Michael and Raué, Hans-Peter and Amanna, Ian J and Slifka, Dawn K and Kreklywich, Craig N and Arduino, Irene and Sulgey, Gauthami and Streblow, Magdalene M and Heise, Mark T and Slifka, Mark K and Streblow, Daniel N},
  title = {Development of a virulent O’nyong’nyong challenge model to determine heterologous protection mediated by a hydrogen peroxide-inactivated chikungunya virus vaccine},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2025},
  volume = {19},
  number = {3},
  pages = {e0012938},
  doi = {10.1371/journal.pntd.0012938}
}
Kostenlos starten →